Trial of Shaladi Churna in the management of Diabetes Mellitus

Phase 3

Completed

• Conditions: Type 2 diabetes mellitus without complications. Ayurveda Condition: MADHUMEHAH/KSHAUDRAMEHAH,

• Registration Number: CTRI/2023/06/054215
• Lead Sponsor: Dr Kalyani Thote

Brief Summary

The prevalence of Diabetes Mellitus is rapidly rising through the globe at an alarming rate, where India leads with largest number of diabetics and become Diabetes Capital of the World. Mdhumeha is one of the most common, chronic, aliment. Now a day’s many formulations are described to treat Madhumeha. Among these Shaladi Churna is one of the drug described in Nighanturatnakar. Shaladi Churna having its own properties like Tridoshahar, Agnideepan, Anuloman, Kaphashaman. It possess anti-diabetic effects through their anti-oxidant properties. Shaladi Churna having Medoghna, Mutral properties. The prevalence rate of DM is 14.6. Diabetes is the 6th leading cause of death in India. We have developed newer medicines, but we come across limitations to OHA and Insulin. Hence there is need for Ayurvedic formulations to prevent the complications of DM and to treat the hyperglycemia. Due to sedentary life style people have no time to take Shodhan Chikitsa like Panchakarma. Thus this disease is increases day by day. Considering all above things the study will be carried out in comparison with conventional modern treatment.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-10-07
• Study Completion: 2024-10-31
• Last Update Posted: 2024-11-17

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 64

Inclusion Criteria

• 1. Age group: between 30 years to 60 years.
• 2. Gender: Male and Female both will be included.
• 3. A known Diabetic on treatment and newly diagnosed Diabetes.
• 4. Patient with fasting blood sugar up to 220 mg/dl & post prandial blood sugar upto 300 mg/dl.
• 5. Patient having HbA1c in between 7 to 9 and Sr. Insulin.

Exclusion Criteria

• 1. IDDM, Acromegaly, Cushing’s syndrome and pancreatic disorder.
• 2. Pregnant and lactating mothers.
• 3. Patients with K/C/O Nephropathy, Neuropathy and Retinopathy.
• 4. Patients with gastrointestinal diseases, Liver diseases, tumours, cardio vascular disease, acute myocardial infarction, immune-compromised disease(HIV).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Glycosylated hemoglobin	at baseline, 4 weeks, 8 weeks and 12 weeks
Blood Sugar levels	at baseline, 4 weeks, 8 weeks and 12 weeks

Trial Locations

Locations (1)

Saneguruji Arogya Kendra; 🇮🇳 Pune, MAHARASHTRA, India

Saneguruji Arogya Kendra

🇮🇳Pune, MAHARASHTRA, India

Dr Kalyani Thote

Principal investigator

7350388787

kalyanithote7026@gmail.com